Past Presentations
-
Development of a Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy
- By: Xiang Li, PhD, Associate Director, Discovery Research, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
DownloadOct 02, 2022 -
Endosomal Escape Vehicle-Oligonucleotide Conjugates for the Targeted Upregulation and Downregulation of Gene Expression
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
DownloadOct 02, 2022 -
Endosomal Escape Vehicles to Enhance the Functional Delivery of Oligonucleotides in Preclinical Models of Neuromuscular Diseases
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 2022 International Conference on Muscle Wasting
DownloadSep 15, 2022 -
Development of a Novel, EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: 7th International Myology Congress
DownloadSep 12, 2022 -
EEV-Conjugated PMO Results in Nuclear Foci Reduction and Aberrant Splicing Correction in Myotonic Dystrophy Cell and Animal Models
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 7th International Myology Congress
DownloadSep 12, 2022 -
Introduction to Entrada Therapeutics and the Endosomal Escape Vehicle (EEV™) Platform to Enhance Oligonucleotide Delivery in Myotonic Dystrophy Type 1
- By: Michael Oldham, MD, Executive Medical Director, Entrada Therapeutics
- At: 2022 Myotonic Dystrophy Foundation (MDF) Annual Conference
DownloadSep 10, 2022 -
Endosomal Escape Vehicle (EEV) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: Parent Project Muscular Dystrophy (PPMD) 2022 Annual Conference
DownloadJun 24, 2022 -
EEV-Conjugated Oligonucleotide Results in Nuclear Foci Reduction and Aberrant Splicing Correction in DM1 Cell and Animal Models
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 13th International Myotonic Dystrophy Consortium Meeting (IDMC-13)
DownloadJun 23, 2022 -
Endosomal Escape Vehicle (EEV) Platform for Enhanced Functional Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 4th Annual RNA Therapeutics Symposium: From Concept to Clinic
DownloadJun 22, 2022